Association between osteoprotegerin, fetuin-A, carotid intima media thickness, and urinary albumin excretion in Type 2 diabetes

Clinical Nephrology

Volumn 80, Issue 1, 2013, Pages 9-16

  Koluman, Basak Unver ^a   Mutluay, Ruya ^b   Derici, Ulver Boztepe ^c   Arinsoy, Turgay ^c   Senlik, Zeynep ^c   Bahar, Burak ^c   Sancak, Banu ^c   Oktan, Suna Özhan ^c   Sindel, Sukru ^c  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Eskisehir Yunus Emre State Hospital   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

CIMT; CRP; Fetuin A hs; Homocysteine; OPG

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FETUIN A; HOMOCYSTEINE; OSTEOPROTEGERIN;

ADULT; ALBUMINURIA; ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; MACROALBUMINURIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; URINARY EXCRETION;

AGED; ALBUMINURIA; ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN;

EID: 84880654239     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107920     Document Type: Article

References (34)

1. Colucci WS, Price DT. Cardiac tumors, cardiac manifestations of systematic diseases, and traumatic cardiac injury. In: Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS (eds). Harrison's Principles of Internal Medicine. USA: McGraw-Hill Companies; 2005. p. 1422.
2. Ishiyama M, Suzuki E, Katsuda J, Murase H, Tajima Y, Horikawa Y, Goto S, Fujita T, Takeda J. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in Type 2 diabetic patients. Diabetes Res Clin Pract. 2009; 85: 189-196.
3. Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonné JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007; 30: 2934-2939.
4. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in Type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008; 23: 1621-1627.
5. Tekin A, Cengiz U, Gültekin S. Nefroloji El Kitabi. 4th ed. Istanbul: Nobel Tip Kitabevi; 2007.
6. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens. 2005; 14: 337-342.
7. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated Type 2 diabetic subjects. J Am Coll Cardiol. 2006; 47: 1850-1857.
8. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in Type 2 diabetes. Diabetes Care. 2006; 29: 1664-1666.
9. Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, Matsuhisa M, Ito T, Imai E, Hori M. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res. 2008; 31: 1163-1170.
10. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in Type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003; 149: 39-42.
11. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in Type 1 diabetic patients with nephropathy. Diabetologia. 2008; 51: 2100-2107.
12. Sultan A, Avignon A, Galtier F, Piot C, Mariano-Goulart D, Dupuy AM, Cristol JP. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in Type 2 diabetic patients. Diabetes Care. 2008; 31: 593-595.
13. Mori K, Jono S, Emoto M, Kawagishi T, Yasumoto H, Konishi T, Furumitsu Y, Shioi A, Shoji T, Inaba M, Nishizawa Y. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and Type 2 diabetes. Angiology. 2010; 61: 86-91.
14. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007; 99: 513-518.
15. Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol. 2001; 12: 555-560.
16. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, Liapis CD. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg. 2010; 51: 114-121.
17. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572-2581.
18. Gül K, Ustün I, Aydin Y, Berker D, Erol K, Unal M, Barazi AO, Delibasi T, Güler S. Carotid intimamedia thickness and its relations with the complications in patients with type 1 diabetes mellitus. Anadolu Kardiyol Derg. 2010; 10: 52-58.
19. Willey KA, Kidd JF, Harris JP, Xu ZR, Yue DK. Albuminuria is an independent predictor of carotid intima-media thickness and atherosclerosis in NIDDM patients. Diabetes Care. 1995; 18: 1502-1503.
20. Nyström T. C-reactive protein: a marker or a player? Clin Sci (Lond). 2007; 113: 79-81.
21. Kajitani N, Shikata K, Nakamura A, Nakatou T, Hiramatsu M, Makino H. Microinflammation is a common risk factor for progression of nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2010; 88: 171-176.
22. Mojahedi MJ, Bonakdaran S, Hami M, Sheikhian MR, Shakeri MT, Aiatollahi H. Elevated serum Creactive protein level and microalbuminuria in patients with type 2 diabetes mellitus. Iran J Kidney Dis. 2009; 3: 12-16.
23. Wu CC, Chen JS, Lu KC, Chen CC, Lin SH, Chu P, Sytwu HK, Lin YF. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta. 2010; 411: 700-704.
24. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but as ymptomatic type 2 diabetic patients. Diabetes Care. 2005; 28: 2176-2180.
25. Brustolin S, Giugliani R, Félix TM. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res. 2010; 43: 1-7.
26. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med. 2008; 8: 533-543.
27. Fischer DC, Nissel R, Puhlmann A, Mitzner A, Tiess M, Schmidt R, Haffner D. Differential effects of short-term growth hormone therapy on the cardiovascular risk profile in patients with chronic kidney disease: a pilot study. Clin Nephrol. 2009; 72: 344-352.
28. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005; 67: 1070-1077.
29. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG; Health ABC Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA. 2008; 300: 182-188.
30. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M, Nordfors L. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005; 67: 2383-2392.
31. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study. Nephrol Dial Transplant. 2006; 21: 2144-2151.
32. Cottone S, Palermo A, Arsena R, Riccobene R, Guarneri M, Mulè G, Tornese F, Altieri C, Vaccaro F, Previti A, Cerasola G. Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease. J Nephrol. 2010; 23: 62-69.
33. Koos R, Brandenburg V, Mahnken AH, Mühlenbruch G, Stanzel S, Günther RW, Floege J, Jahnen-Dechent W, Kelm M, Kühl HP. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J. 2009; 30: 2054-2061.
34. Ametov AS, Karpova EV, Ivanova EV. [Current approaches to controlling type 2 diabetes]. Ter Arkh. 2009; 81: 20-27